– USA, CA – Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Dr. Preston Klassen (M.D.) to its Board of Directors.
About Dr. Preston S. Klassen
Dr. Klassen recently joined Regulus Therapeutics as President and Head of Research and Development. Dr. Klassen is a nephrologist by training who brings over 20 years of experience in pharmaceuticals, including positions in leadership, medical affairs, and research and development across multiple therapeutic areas. Most recently, he served as the President and CEO of Metacrine. Before that, he was an EVP and Head of R&D at Arena Pharmaceuticals, CMO and President at SANIFIT, and SVP and Head of Global Development at Orexigen Therapeutics. Previously, while at Amgen, he held multiple leadership roles, including Executive Medical Director and Therapeutics Area Head for Nephrology.
Dr. Klassen earned his M.D. from the University of Nebraska Medical Center and completed both his residency in internal medicine and fellowship in nephrology as well as his Master’s in Health Sciences at Duke University Medical Center.
About Regulus
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.
For more information: https://www.regulusrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
